



Sessie 7 Cel- en gentherapie als geneesmiddel

Progr.	Dossiernr	Titel	Projectleider/ instelling	Einddatum
Dof	94507606	Pharmacogenetic testing in the clinical setting: is screening for TPMT genotype a cost-effective treatment strategy? The first prospective randomized controlled trial within the Dutch health care system.	Prof. dr. B. Franke	1-3-2012
DOf	171102022	Cost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention with stent implantation: optimization of treatment	Deneer	1-9-2017
DOf	171102024	Personalized prophylaxis of venous thrombosis based on genetic and other risk factors in a population at risk.	Cannegieter	1-10-2015
OR4	836041013	TailoRing anti-androgEn therapy For metastatic castration resistant prostate cancer based on early tumor response markers In combiNation with drug Exposure measurement (REFINE-project)	Dr. N.P. van Erp	1-10-2018